#China #Beijing #JensClip #Jenscare #LuX-Valve

Jenscare Unveils Groundbreaking Heart Valve Solutions at TCT 2025

Beijing, Oct. 29, 2025 /PRNewswire/ - Jenscare Scientific Co., Ltd., a pioneering medical device company listed on the Hong Kong Stock Exchange (HKEX: 9877), captured attention at the TCT 2025 conference held in the U.S. by presenting impressive clinical outcomes from its diverse portfolio of cardiovascular products. The centerpiece of the presentation was the six-month follow-up results of the TRINITY Trial for the LuX-Valve Plus, alongside the one-year outcomes of the JensClip and Ken-Valve systems, which are designed to cater to patients facing high surgical risks.

LuX-Valve Plus: A Breakthrough in Tricuspid Valve Treatments

The LuX-Valve Plus is a self-developed transcatheter tricuspid valve replacement (TTVR) system that offers a revolutionary solution for patients suffering from severe tricuspid regurgitation. Led by Professor Thomas Modine from CHU de Bordeaux-Haut-Leveque in France, the TRINITY Trial enrolled 161 participants from 20 centers globally. The data highlighted an impressive device success rate of 97%, with an average operation time of 41.6 minutes. Safety metrics also painted a promising picture, with a composite adverse event rate of only 19.9% at the six-month mark.

A remarkable 94.4% of patients reported a significant improvement in their tricuspid regurgitation grade, demonstrating the effectiveness of this cutting-edge valve replacement. Professor Modine emphasized that the LuX-Valve Plus is engineered with an anchor mechanism designed specifically for tricuspid valve applications, and it requires low imaging quality, which could mitigate procedural complexities.

JensClip and Ken-Valve: Expanding Treatment Options

Aside from the LuX-Valve Plus, Jenscare also unveiled the JensClip, a proprietary transcatheter mitral valve repair (TMVr) device evaluated in a trial led by Professor Vinicius Esteves from the University Hospitals in Cleveland, U.S. The study involved 114 patients and reported a remarkable device success rate of 95% at 30 days post-procedure, demonstrating continuous improvement in patient quality of life and mitral regurgitation rates. With an average KCCQ score increase of 20 points, JensClip’s effectiveness in treating symptomatic degenerative mitral regurgitation (DMR) underlines its innovative self-locking design.

Furthermore, the Ken-Valve, a transcatheter aortic valve replacement (TAVR) system, was also showcased with one year of results presented by Professor Anson Cheung from St. Paul's Hospital in Canada. The study reported a success rate of 97%, with patients showing substantial benefits in terms of aortic regurgitation reduction and overall quality of life improvements.

Conclusion

Jenscare's robust portfolio for structural heart diseases presents a promising future for effective treatment options for patients deemed high-risk for conventional surgeries. The company is not only expanding its product offerings but is also committed to further clinical follow-ups and evidence collection to support its advancements in interventional cardiovascular technologies. Jenscare's innovative approaches, particularly with the LuX-Valve Plus's advancement, are designed to meet the growing demands for effective solutions in complex cardiac conditions, operating within this critical area of healthcare.

In summary, Jenscare's revelations at TCT 2025 mark another significant stride toward enhancing patient outcomes in structural heart disease treatments, positioning itself at the forefront of medical innovation in the cardiovascular field.